Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Suicidality Screening For All New Drugs Still On The Table After Draft Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA lists eight drug classes where it will recommend prospective assessment of suicidality risk, but it invites comments on broadening the criteria.

You may also be interested in...

DTC Advertising For ADHD, Acne, Antidepressant Meds Could Shift After FDA Study

Seeking to better understand how adolescents process information in direct-to-consumer ads, agency proposes survey using web-based promotions for fictitious treatments.

FDA Drops “Suicidality” Term, Urges Broader Risk Assessment During Development

Revised draft guidance retains eight categories of drugs to be evaluated for suicidal ideation and behavior in clinical trials, but says assessments could be conducted more broadly and “encourages” sponsors to discuss the possibility with the review division.

FDA Suicidality Reassessments Will Be Made At Division Level, Not Through Guidance

Decisions on whether to add drugs or classes of drugs to a list FDA has published of investigational products that need suicidality assessments will be made at the division level, the agency says.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts